Eli Lilly is awaiting an FDA decision for a new indication for Mounjaro to reduce the risk of a major adverse cardiovascular event (MACE) in patients with type 2 diabetes mellitus (T2DM)
It simultaneously activates three hormone receptors that play central roles in metabolism, appetite regulation, and energy balance: Glucagon-like peptide-1 (GLP-1) receptor Glucose-dependent insulinotropic polypeptide (GIP) receptor Glucagon receptor Previous weight loss medications have targeted one or two of these pathways
However, measurable amounts of tirzepatide continue circulating for the full seven-day interval between doses, which is why the medication is dosed weekly rather than daily
The clients who see the most dramatic improvements are those who also focus on nutrition, exercise, sleep, and stress management
In Komodo Healthcare Map, semaglutide users had 36% fewer all-cause hospitalizations (RR 0.63 [95% CI 0.570.69]), 36% fewer ASCVD-related hospitalizations (RR 0.64 [95% CI 0.550.74]), 7% fewer all-cause outpatient visits (RR 0.93 [95% CI 0.900.95]), and 13% fewer ASCVD-related outpatient visits (RR 0.87 [95% CI 0.800.94]) vs DPP-4i users (Fig